Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Prime Medicine (PRME) EBITDA Margin (2024 - 2025)

Historic EBITDA Margin for Prime Medicine (PRME) over the last 2 years, with Q3 2025 value amounting to 4125.63%.

  • Prime Medicine's EBITDA Margin rose 209585800.0% to 4125.63% in Q3 2025 from the same period last year, while for Sep 2025 it was 3301.44%, marking a year-over-year increase of 240834400.0%. This contributed to the annual value of 6566.07% for FY2024, which is N/A changed from last year.
  • Prime Medicine's EBITDA Margin amounted to 4125.63% in Q3 2025, which was up 209585800.0% from 4716.23% recorded in Q2 2025.
  • Prime Medicine's EBITDA Margin's 5-year high stood at 1937.52% during Q4 2024, with a 5-year trough of 25084.21% in Q3 2024.